Joaquim Bellmunt, MD, PhD
Enriched profileProfessor of Medicine, Harvard Medical School; Director, Bladder Cancer Center, Genitourinary Oncology Program, Dana-Farber Cancer Institute · Dana-Farber Cancer Institute
Joaquim Bellmunt is Professor of Medicine, Harvard Medical School; Director, Bladder Cancer Center, Genitourinary Oncology Program, Dana-Farber Cancer Institute at Dana-Farber Cancer Institute. OpenAlex indexes 1,139 publications with 67,263 citations (h-index 107); ClinicalTrials.gov lists 8 registered studies with this person as an investigator.
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Joaquim Bellmunt Molins is Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute, Boston, MA, Director, Bladder Cancer Center, Genitourinary Oncology Program. The public record shows 1,139 publications with 67,263 citations (h-index 107), centered on Bladder and Urothelial Cancer Treatments, Urinary and Genital Oncology Studies, Renal cell carcinoma treatment. It also documents an investigator role on 8 registered clinical trials.
- Most recent indexed publication: 2026 · Molecular oncology
- Top research focus: Bladder and Urothelial Cancer Treatments
- 8 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 30 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 456.
Clinical & industry
trials, payments and federal fundingNot shown. No U.S. clinical registration on file.
Federally funded research awards.
This is a research profile, built on the published record. There's no U.S. clinical registration (NPI) on file, so facts that hang off one (clinical specialty, industry payments) aren't shown. We'd rather leave a gap than guess. Why? →
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
450 Brookline Avenue, Boston, MA 02215
Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
Sponsor: Dana-Farber Cancer Institute
- Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)
Sponsor: Associació per a la Recerca Oncologica, Spain
- Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer
Sponsor: Associació per a la Recerca Oncologica, Spain
Industry payments
Not shown. This person has no U.S. clinical registration (NPI) on file, so we can't reliably tie industry payments reported to CMS to them. We'd rather leave a gap than guess. Why? →
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Tumor B-cell infiltration in platinum-treated advanced muscle-invasive urothelial carcinoma.
Molecular oncology
Article2026 - ctDNA Dynamics and Recurrence Patterns after Organ-Sparing Trimodality Therapy for Bladder Cancer.
Clinical cancer research
Article2026 - Uncovering the role of ETS2 in prostate cancer pathogenesis: relationship with p53 and ERG.
Molecular biology reports
Article2026 - Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.
CA: a cancer journal for clinicians
Article2026
Most-cited works
by citation count (OpenAlex)Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- X / Twitter
x.com/OncoBellmunt
- LinkedIn
linkedin.com/in/joaquim-bellmunt-3a032a294
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Other
esmo.org/about-esmo/biographies/joaquim-bellmunt
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →esmo.org ↗ - Spotify
oncbrothers.com/bladdercancer-2025
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncbrothers.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →esmo.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →fundacioolgatorres.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →esmo.org ↗
Editorial & leadership roles
journal and society appointments- Chairman
Gelb Center, Lank Center of Genitourinary Oncology, Dana-Farber/Brigham and Women's Cancer Center
2016verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bellmuntoncologia.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bellmuntoncologia.com ↗
- Chairman
Advanced Bladder Cancer Committee, European Organization for Research and Treatment of Cancer (EORTC), Genitourinary Group, 2006-2011 (past-president/chair per subsequent bios)
2011verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →esmo.org ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bellmuntoncologia.com ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bellmuntoncologia.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bellmuntoncologia.com ↗
- Former Director
Bladder Cancer Center, Beth Israel Deaconess Medical Center (historical/legacy affiliation, transitioned away March 2013 …
2013verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Media & interviews
press, podcasts and appearances- OncBrothers podcast/video: "How to Treat Bladder Cancer in 2025 with Dr. Joaquim Bellmunt," published March 10
2025, discusses NIAGARA trial, perioperative immunotherapy, BCG-refractory disease …
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncbrothers.com ↗ - OncoDaily feature "Joaquim Bellmunt: Proud of learning from negative trials" (Sept 1, 2024)
covering the INDUCOMAIN phase II trial …
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗ - The Uromigos podcast appearance
September 21, 2022, discussing a negative trial result and its implications for the GU oncology field
2022provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancerletter.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute